目的 探究多西紫杉醇联合顺铂辅助化疗对非小细胞肺癌的疗效以及不良反应影响.方法 回顾性分析246例非小细胞肺癌患者的临床资料.按照不同的治疗方式分为对照组和研究组,对照组采用多西紫杉醇治疗,研究组采用多西紫杉醇联合顺铂治疗,对比两组的近期治疗有效率,不良反应发生率以及功能状态改善情况.结果 研究组近期总有效率为51.22%显著高于对照组29.26%(P﹤0.01);两组发生的各项不良反应(如:恶心呕吐、疲乏无力、白细胞减少等)率均无明显差异(P﹥0.05);两组治疗后,功能状态评分均得到显著提高,研究组提高幅度更大(P﹤0.01);两组患者1年、2年生存率的比较均无明显差异(P﹥0.05).结论 多西紫杉醇联合顺铂辅助化疗对非小细胞肺癌的疗效甚佳,并且不会增加不良反应,还可以改善患者的功能状态,具有临床实际应用价值.%Objective To explore the therapeutic and adverse effects of adjuvant therapy of docetaxel combined with cisplatin in the treatment of non-small cell lung cancer (NSCLC) patients. Method The clinical data of 246 patients treat-ed for NSCLC were reviewed retrospectively. The patients were divided into two groups on the basis of theic treatment, with the control group using docetaxel and the study group receiving docetaxel + cisplatin. The short-term overall re-sponse rate, incidence of adverse reactions and function of the two groups were evaluated and compared. Result The short-term overall response rate in the study group was 51.22%, and was significantly higher than that in control group as 29.26%(P<0.01). Yet, there was no significant difference observed in respect of the incidence of adverse reactions (such as nausea and vomiting, fatigue, leukopenia and so on) in the two groups (P>0.05). The function scores of both groups were significantly improved after treatment, and a significant increment was observed in the study group (P<0.01). Be-sides, the 1 and 2-year survival of the two groups were also similar (P>0.05). Conclusion Adjuvant chemotherapy of docetaxel combined with cisplatin is highly effective in the treatment of NSCLC, which induces few adverse reactions yet improves the functional status of the patients, therefore, it is of practical value for clinical application.
展开▼
